Invivomab anti mouse cd8α clone 53 6.7

All mice were randomized prior to treatment. Once tumors become established (average tumor size of 65 mm² or 19 mm², day 17–18 or 8 after mEER and MOC2 inoculation, respectively) treatment was initiated over two weeks. The chemoradiotherapy treatment combined a fractionated tumor-directed radiation regimen (10 X 3Gy daily) (see Supplementary Material for further details) with weekly cisplatin (83μg/mouse; Selleck Chemicals) intraperitoneal injections. The immunomodulatory treatment combined weekly intraperitoneal injections of cyclophosphamide (2 mg/mouse; TCI Chemicals) and continuous oral administration of L-NIL (0.2%; Enzo Life Sciences) in the drinking water ad libitum.
For CD8 depletion experiments, all mice received the combinatory treatment and were injected with 1 mg depleting InVivoMAb anti-mouse CD8α (clone 53–6.7; BioXCell) or InVivoMAb rat IgG2a isotype control (clone 2A3; BioXCell) 2 days prior the treatment, and further treated with weekly 250 μg antibodies for 3 consecutive weeks.

Six-to-eight-week-old mice were purchased from The Jackson Laboratory (United States). Mice were injected subcutaneously at both flanks with 1 × 10⁶ A20 lymphoma cells (WT BALB/c) or LLC cells (WT C57BL/6 (B6)). When tumors reached 100 mm³, tumor-bearing recipient mice were randomized into groups and treated as indicated. All mice were maintained under specific pathogen-free conditions in the vivarium facility of City of Hope. Animal work was approved by the Institutional Animal Care and Use Committee of City of Hope. The following drugs were used: InVivoMAb anti-mouse CD8α (clone 53-6.7), InVivoPlus anti-mouse PD-1 (clone RMP1-14; both from BioXCell).